| Project/Area Number |
23K06454
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 49020:Human pathology-related
|
|---|
| Research Institution | Tokai University |
|---|
Principal Investigator |
カレーラス ジュアキム 東海大学, 医学部, 講師 (90637191)
|
|---|
| Project Period (FY) |
2023-04-01 – 2026-03-31
|
| Project Status |
Granted (Fiscal Year 2023)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2025: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2024: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2023: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | lymphoma / targeted sequencing / immuno-oncology / immune microenvironment / immune checkpoint / molecular pathology / hematological neoplasia / NGS / リンパ腫 / 免疫腫瘍学 / 人工知能 / 免疫チェックポイント / 次世代シーケンシング |
|---|
| Outline of Research at the Start |
この研究では、集学的アプローチを使用してリンパ腫の免疫チェックポイントを分析しています。B細胞性リンパ腫の解析を行います。重要なマーカーは、PD-L1、CSF1R、IL-10 などです。免疫組織化学、遺伝子発現解析、コピー数・LOH解析、次世代標的変異解析などを実施します。解析には、従来のバイオインフォマティクスだけでなく、人工知能（機械学習、ニューラルネットワーク）なども含まれます。
|
| Outline of Annual Research Achievements |
BCL6-rearrangement (BCL6-R) is associated with a favorable prognosis of follicular lymphoma (FL), but the mechanism is unknown. We analyzed the clinicopathological, immune microenvironment (immune checkpoint, immuno-oncology markers), and mutational profiles of 10 BCL6-R-positive FL, and 19 BCL6-R-positive diffuse large B-cell lymphoma (DLBCL) cases (both BCL2-R and MYC-R negative). A custom-made panel included 168 genes related to aggressive B-cell lymphomas and FL. Both BCL6-R-positive FL and BCL6-R-positive DLBCL had a common mutational profile; but also, differences. DLBCL cases had a higher density of microenvironment markers.
|
| Current Status of Research Progress |
Current Status of Research Progress
2: Research has progressed on the whole more than it was originally planned.
Reason
The project is progressing well, and as expected.
|
| Strategy for Future Research Activity |
We will continue the evaluation of immuno-oncology markers in larger series of cases and plan next set of NGS analysis.
|
